Compare CRAI & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRAI | NVAX |
|---|---|---|
| Founded | 1965 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1998 | 1996 |
| Metric | CRAI | NVAX |
|---|---|---|
| Price | $168.33 | $8.05 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | ★ $245.00 | $11.33 |
| AVG Volume (30 Days) | 127.1K | ★ 3.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | 20.77 | ★ 309.76 |
| EPS | ★ 8.14 | N/A |
| Revenue | $751,583,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $5.14 | N/A |
| P/E Ratio | $20.99 | ★ N/A |
| Revenue Growth | 9.33 | ★ 64.69 |
| 52 Week Low | $132.17 | $6.20 |
| 52 Week High | $227.29 | $11.85 |
| Indicator | CRAI | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 48.79 | 47.45 |
| Support Level | $152.37 | $7.70 |
| Resistance Level | $179.62 | $10.10 |
| Average True Range (ATR) | 7.81 | 0.29 |
| MACD | -2.06 | 0.11 |
| Stochastic Oscillator | 21.81 | 75.00 |
CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.